Financial Review: Inhibikase Therapeutics (NASDAQ:IKT) & Vor Biopharma (NASDAQ:VOR)

Inhibikase Therapeutics (NASDAQ:IKT) and Vor Biopharma (NASDAQ:VOR) are both small-cap manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Profitability

This table compares Inhibikase Therapeutics and Vor Biopharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-63.82%	-58.03%
Vor Biopharma	N/A	N/A	N/A

Valuation and Earnings

This table compares Inhibikase Therapeutics and Vor Biopharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260,000.00	441.39	-$27.52 million	N/A	N/A
Vor Biopharma	N/A	N/A	N/A	($273.20)	-0.10

Vor Biopharma has lower revenue, but higher earnings than Inhibikase Therapeutics.

Institutional and Insider Ownership

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 7.3% of Inhibikase Therapeutics shares are held by insiders. Comparatively, 0.5% of Vor Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and target prices for Inhibikase Therapeutics and Vor Biopharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1	0	0	0	1.00
Vor Biopharma	2	3	5	1	2.45

Vor Biopharma has a consensus target price of $77.83, suggesting a potential upside of 186.26%. Given Vor Biopharma’s stronger consensus rating and higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Inhibikase Therapeutics.

Risk & Volatility

Inhibikase Therapeutics has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Vor Biopharma has a beta of 2.07, indicating that its share price is 107% more volatile than the S&P 500.

Summary

Vor Biopharma beats Inhibikase Therapeutics on 8 of the 10 factors compared between the two stocks.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.

About Vor Biopharma

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company’s eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.